<DOC>
	<DOCNO>NCT00791219</DOCNO>
	<brief_summary>The objective study compare relative efficacy safety SUBA™-Itraconazole Capsules ( HalcyGen Ltd ) already market oral formulation itraconazole SPORANOX® ( itraconazole ) capsule ( Janssen Pharma ) treatment onychomycosis toenail . Both test reference formulation also compare placebo formulation test superiority .</brief_summary>
	<brief_title>Study Comparing SUBA™-Itraconazole With SPORANOX® ( Itraconazole ) Treatment Onychomycosis</brief_title>
	<detailed_description>Randomized , Double-Blind , Multiple-Site , Placebo-Controlled , Parallel design study compare dose regimen 100 mg approximately 30 minute prior breakfast 12 week SUBA™-Itraconazole 50 mg capsule ( HalcyGen Ltd ) approve dose regimen 200 mg take breakfast SPORANOX® ( itraconazole ) 100 mg capsule ( Janssen Pharma ) . Patients randomly assign 3:3:1 ratio test product 100 mg once-a-day : reference product 200 mg once-a-day : placebo once-a-day . respectively . The patient complete 5 visit : baseline/screening ( within 28 day randomization ) , Day 1 ( randomization ) , Week 6 , Week 12 Week 24 .</detailed_description>
	<mesh_term>Onychomycosis</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<criteria>1 . Male nonpregnant , non lactate female 18 year age old . 2 . Signed informed consent form , meet criteria current FDA regulation . 3 . If female child bear potential , negative urine pregnancy test baseline randomization visit prepare abstain sexual intercourse use reliable method contraception study ( e.g. , condom spermicide , IUD , oral , injected , transdermal implant hormonal contraceptive ) . 4 . Clinical diagnosis onychomycosis least one great toenail 5 . Clinical sign symptom onychomycosis severely affected great toenail least moderate severity define least 25 % 75 % infected toenail combine severity score least 4 use Nail Infection Rating Scale ( see Appendix A ) . 6 . At least 2mm clear nail affect toe proximal nail fold deep extend onychomycosis . 7 . Positive KOH stain confirmation fungal nail infection 8 . Positive mycological culture know fungal dermatophyte consistent onychomycosis infection least one great toenail . 1 . Females pregnant , lactate likely become pregnant study . 2 . Negative KOH stain 3 . Negative mycological culture fungal dermatophytes consistent onychomycosis infection . 4 . Combined score less 4 Nail Infection Rating Scale severely affect great toenail . 5 . Patient superficial onychomycosis significant dystrophy target toenail Investigators opinion would impair evaluation onychomycosis . 6 . Patient total dystrophic proximal subungual onychomycosis target toenail . 7 . Presence mycotic spike patient exclusively lateral groove involvement target toenail . 8 . Less 25 % 75 % severely infected great toenail affect . 9 . Target toenail thickness great 3mm . 10 . No new nail growth target nail previous 6 month . 11 . Onychomycosis cause dermatophyte ( e.g . mold infection , Candida spp bacterial infection ) . 12 . Previous treatment onychomycosis toenail within last 12 month unresponsive treatment . 13 . Previous treatment within previous 2 month systemic antifungal therapy within previous 2 week topical antifungal therapy . 14 . Significant history current evidence chronic infectious disease , system disorder , organ disorder medical condition Investigator 's opinion would place study patient undue risk participation could jeopardize integrity study evaluation . 15 . Immunocompromised either concomitant disease ( e.g . HIV ) , ongoing treatment ( e.g . chemotherapy ) . 16 . Current history psoriasis within previous 12 month . 17 . Evidence ventricular dysfunction congestive heart failure ( CHF ) history CHF . 18 . History diabetes . 19 . Previous hypersensitivity imidazole azole compound . 20 . Liver Function Test result screen twice upper limit normal range hematology clinical chemistry test result would contraindicate dose itraconazole . 21 . Use within previous 3 month anticipate use study drug know affect bioavailability oral itraconazole otherwise contraindicate take itraconazole detailed product label SPORANOX® ( Appendix B ) . 22 . Receipt drug part research study within 30 day prior dose . 23 . Previous dose study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Onychomycosis</keyword>
</DOC>